42 results about "Melanoma patient" patented technology

Methods to treat cancer patients, especially melanoma patients, who have BRAF mutations and have become resistant to BRAF mutant kinase inhibitors employ inhibitors of multiple receptor tyrosine kinases. In addition, methods are described for identifying pharmaceutical compositions and drugs that will be successful in treating these patients.

The invention discloses the application of the ASMT / CYP1A1 molecular signature in predicting the clinical prognosis or immune characteristics of solid tumors. The inventors studied the transcriptome and genome data of 6,658 tumor samples from 14 kinds of solid tumors, and conducted a large-scale bioinformatics analysis, confirming that the ratio of ASMT / CYP1A1 in different solid tumors is related to the clinical prognosis and tumor mutation level of patients. , Tumor neoantigen load relationship. Among them, the clinical prognosis of cervical cancer, gastric cancer, and melanin patients in the High Index group was more impressive. The results of multivariate analysis showed that ASMT / CYP1A1 was an independent predictor of clinical prognosis in cancer patients; in addition, in colorectal cancer, head and neck squamous Among patients with cancer, kidney cancer, liver cancer, prostate cancer, and melanoma, although the prognosis of patients in the Low Index group is poor, there are more mutation loads and / or tumor neoantigens, suggesting that patients in this group are more likely to benefit from immunotherapy. benefit.

Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.